AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06164353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially demineralized dentin graft covered with a collagen membrane
Description: The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
Study NCT06164353 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Partially demineralized dentin graft covered with a collagen membrane
Description: The stored tooth will undergo grinding using the tooth transformer device. The produced particulate dentin graft will be of a particle size 400-800 µm. Afterwards, these particles will undergo partial demineralization by immersion in in 2% HNO3 for 10 minutes. Then, it will be washed twice using phosphate buffered saline. The exposed implant threads will be covered by partially demineralized autogenous dentin graft in the test group
Study NCT05565222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam or temocillin
Description: Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)
Study NCT05565222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 2 g every 8 hours by intravenous route (adjusted in case of renal failure)
Study NCT05573165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 hours of preoperative fasting for breast milk
Description: 3 hours of preoperative fasting for breast milk
Study NCT05573165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours of preoperative fasting for breast milk
Description: 4 hours of preoperative fasting for breast milk
Study NCT04827056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally, as individual films in the SL space.
Study NCT04827056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally, as individual films in the SL space.
Study NCT04827056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.
Study NCT04827056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.
Study NCT04827056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.
Study NCT06781697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
Study NCT06781697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).
Study NCT06781697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus VR headset
Description: Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.
Study NCT04309266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amadeo by Tyromotion
Description: Distal upper extremity/hand robot for robot-assisted therapy
Study NCT04309266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Learning Protocol for Stroke
Description: Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
Study NCT05465421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation
Description: Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later
Study NCT05465421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow aspiration from maxillary tuberosity and BMMNCs separation to be seeded on PRF and used for socket preservation
Description: Local anaesthesia will be administered by infiltration or nerve block to achieve the necessary anaesthesia to allow extraction of the indicated tooth Extraction will be done as atraumatically as possible removing any pathosis found that may interfere with bone formation A trapezoidal flap will be created above the extraction socket to allow closure of the surgical site.~BMMNC will be seeded on platelet rich fibrin and inserted in the socket The flap will be closed by interrupted sutures using 5-0 sutures. implant placement 3 months later
Study NCT03943303 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Natural gamma radiation from the monazite sands
Description: Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
Study NCT04827056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.
Study NCT03943303 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Normal sands exposure patients
Description: Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
Study NCT05873257 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biatain Fiber Ag applied to participants
Description: Intervention involving a wound gelling fiber dressing with silver
Study NCT04827056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ethanol Infusion
Description: Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
Study NCT04827056 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol Infusion
Description: Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
Study NCT05868148 — intervention group
Intervention type: DEVICE
Intervention: Shoulder iD™ Primary Reversed Glenoid
Description: Device implant via reversed total shoulder arthroplasty
Study NCT04827056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Reactivity Condition
Description: Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
Study NCT05203939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 Low Dose
Description: subretinal injection of up to 1.66 × 10\^10 vg/mL
Study NCT05203939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 Med Dose
Description: subretinal injection of upto 3.33 × 10\^10 vg/mL
Study NCT04827056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PTSD Reactivity Condition
Description: Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
Study NCT04827056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Cue Reactivity
Description: Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
Study NCT04827056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Cue Reactivity
Description: Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
Study NCT05203939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU400 High Dose
Description: subretinal injection of upto 1.66 × 10\^11 vg/mL
Study NCT06309810 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs).
Study NCT06567561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Foods Plant-Based Diet
Description: Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.
Study NCT06567561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Firehouse Diet
Description: Usual firehouse meals.
Study NCT04945343 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Growing Rods
Description: Growing Rods(GR), are implants used to correct pediatric scoliosis deformity. They attempt to allow the growth of the spine and thorax while controlling curve progression to preserve normal lung volume.
Study NCT04280471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Receive OpenBiome FMT Capsule DE PO
Study NCT06242340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm group bathing 24 hours after birth.
Description: Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
Study NCT06242340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preterm group bathing 48 hours after birth.
Description: Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
Study NCT06242340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early term group bathing 24 hours after birth.
Description: Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
Study NCT06242340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early term group bathing 48 hours after birth.
Description: Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
Study NCT04420780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener
Description: The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
Study NCT04420780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)
Description: The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
Study NCT04373668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Time Care Activities Programme
Description: Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
Study NCT04941313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D229
Description: 3D229 is an investigational drug.
Study NCT04941313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05717790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Description: Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT .
Study NCT05717790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT .
Study NCT05717790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
Study NCT05717790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
Study NCT05717790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study NCT05717790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Study NCT05717790 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
Study NCT05717790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
Study NCT06225245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Stimulation (ESS)
Description: ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
Study NCT05762458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine
Description: Ammoxetine hydrochloride enteric-coated tablets
Study NCT05762458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to Ammoxetine.
Study NCT05762458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to Ammoxetine.
Study NCT04668820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: video Pediatric Gait, Arms, Legs and Spine (V-pGALS)
Description: The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
Study NCT05757830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UANGO suite exoskeleton
Description: Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3.
Study NCT06442228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spermiogram test
Description: Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported.
Study NCT04980170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Description: patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
Study NCT04980170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin with Clavulanic Acid 635mg
Description: patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
Study NCT05580510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator.